Document is current
Any future updates will be listed below
-
Authors
Freeman, Jincong Q. https://orcid.org/0000-0002-1119-2146
Shubeck, Sarah
Howard, Frederick M. https://orcid.org/0000-0002-6039-1141
Chen, Nan
Nanda, Rita https://orcid.org/0000-0001-5248-0876
Huo, Dezheng https://orcid.org/0000-0002-4041-1678
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-22-071)
Susan G. Komen (TREND21675016)
- License Information
-
More Information
Article History
Received: 6 December 2022
Accepted: 20 April 2023
First Online: 6 May 2023
Competing interests
: R.N. declares advisory board involvement with Arvinas, AstraZeneca, BeyondSpring, Celgene, FujiFilm, Genentech/Roche, Gilead, Infinity, iTeos, Merck, OBI Pharma, OncoSec, Pfizer, Relay Therapeutics, SeaGen, Sun Pharma, and Taiho outside the submitted work. The remaining authors declare no competing interests.
